Pharma Pioneer

Boundless Bio Initiates Phase 1/2 Trial with First Patient Dosed for BBI-825 in Cancer Patients with Resistance Genes

16 May 2024
2 min read

Boundless Bio, a clinical-stage oncology firm, has initiated a Phase 1/2 clinical trial for BBI-825, an innovative oral inhibitor of ribonucleotide reductase (RNR), as part of the STARMAP study. This marks the company's second extrachromosomal DNA (ecDNA)-directed therapy (ecDTx) to enter clinical development. BBI-825 has shown promise in preclinical trials by inhibiting tumor growth and tackling resistance in MAPK pathway-activated tumors

The STARMAP trial will assess BBI-825's safety, pharmacokinetics, and preliminary antitumor activity, either as a single agent or in combination with other targeted therapies. The study will focus on patients with colorectal cancer that has developed resistance to targeted therapies, a significant challenge in cancer treatment. The first patient has already been dosed in the trial, which is an open-label, non-randomized, three-part design. 

Boundless Bio's Spyglass platform has identified synthetic lethal targets crucial for ecDNA formation and function in oncogene-amplified cancers. The company aims to expand the application of BBI-825 to broader patient populations if the trial data are supportive. BBI-825 works by depriving ecDNA-reliant cancer cells of the building blocks of DNA, thus inhibiting their growth and survival. 

The company is headquartered in San Diego and is developing a new paradigm in cancer therapeutics by targeting ecDNA, a root cause of oncogene amplification found in over 14% of cancer patients. Boundless Bio's first ecDNA-directed therapy, BBI-355, is also undergoing clinical trials. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Initial Clinical Trial Results: ME-344 Combined with Avastin® for Relapsed Metastatic Colorectal Cancer Treatment
Pharma Pioneer
2 min read
Initial Clinical Trial Results: ME-344 Combined with Avastin® for Relapsed Metastatic Colorectal Cancer Treatment
16 May 2024
In a recent Phase 1b clinical trial, MEI Pharma's drug candidate ME-344, when combined with bevacizumab, demonstrated positive results in treating patients with relapsed metastatic colorectal cancer (mCRC).
Read →
Processa Showcases Dual Abstracts at AACR's 2024 Gathering, Featuring NGC-Cap's Phase 1b Clinical Trial Insights
Pharma Pioneer
3 min read
Processa Showcases Dual Abstracts at AACR's 2024 Gathering, Featuring NGC-Cap's Phase 1b Clinical Trial Insights
16 May 2024
Processa Pharmaceuticals, a clinical-stage company, has introduced promising results from a Phase 1b study of its Next Generation Capecitabine (NGC-Cap) at the AACR Annual Meeting.
Read →
Enliven Therapeutics Unveils Favorable Early Data from Phase 1 ELVN-001 Trial for CML Patients
Pharma Pioneer
2 min read
Enliven Therapeutics Unveils Favorable Early Data from Phase 1 ELVN-001 Trial for CML Patients
16 May 2024
Enliven Therapeutics has reported encouraging early results from a Phase 1 clinical trial of ELVN-001, a novel small molecule kinase inhibitor targeting chronic myeloid leukemia (CML).
Read →
New Breakthrough for Metastatic Cancer Therapies: FDA Approves Lamassu's Innovative Treatment Protocol for Clinical Trials
Pharma Pioneer
2 min read
New Breakthrough for Metastatic Cancer Therapies: FDA Approves Lamassu's Innovative Treatment Protocol for Clinical Trials
16 May 2024
Lamassu Biotech has received approval from the FDA to commence Phase 1/2a clinical trials for its innovative cancer treatment, SA53-OS.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.